Natus Medical Inc (NASDAQ:BABY) Receives $36.00 Average PT from Analysts

Natus Medical Inc (NASDAQ:BABY) has been assigned an average rating of “Hold” from the six analysts that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $36.00.

BABY has been the topic of several recent research reports. BidaskClub lowered shares of Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research lowered shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th. TheStreet lowered shares of Trinity Industries from a “b” rating to a “c” rating in a report on Thursday, April 25th. Finally, ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st.

In related news, Director Robert A. Gunst sold 8,000 shares of Natus Medical stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $26.73, for a total transaction of $213,840.00. Following the transaction, the director now owns 26,392 shares in the company, valued at approximately $705,458.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert A. Gunst sold 2,000 shares of Natus Medical stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $26.25, for a total transaction of $52,500.00. Following the transaction, the director now owns 26,392 shares in the company, valued at approximately $692,790. The disclosure for this sale can be found here. Insiders have sold a total of 48,515 shares of company stock worth $1,264,239 in the last 90 days. Company insiders own 1.65% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Comerica Bank increased its stake in Natus Medical by 1.2% during the 1st quarter. Comerica Bank now owns 33,383 shares of the medical equipment provider’s stock worth $856,000 after buying an additional 384 shares during the period. Piedmont Investment Advisors Inc. increased its stake in Natus Medical by 4.8% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 8,406 shares of the medical equipment provider’s stock worth $213,000 after buying an additional 387 shares during the period. Royce & Associates LP increased its stake in Natus Medical by 55.4% during the 1st quarter. Royce & Associates LP now owns 1,100 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 392 shares during the period. Thrivent Financial for Lutherans increased its stake in Natus Medical by 2.2% during the 4th quarter. Thrivent Financial for Lutherans now owns 23,916 shares of the medical equipment provider’s stock worth $814,000 after buying an additional 526 shares during the period. Finally, Citigroup Inc. increased its stake in Natus Medical by 7.5% during the 4th quarter. Citigroup Inc. now owns 11,323 shares of the medical equipment provider’s stock worth $385,000 after buying an additional 789 shares during the period. Institutional investors and hedge funds own 91.56% of the company’s stock.

Shares of BABY traded down $0.04 during mid-day trading on Friday, reaching $26.03. The company had a trading volume of 7,348 shares, compared to its average volume of 180,742. The firm has a market capitalization of $879.73 million, a PE ratio of 18.20 and a beta of 0.57. The company’s fifty day simple moving average is $25.13. Natus Medical has a fifty-two week low of $23.53 and a fifty-two week high of $37.90. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.18 and a current ratio of 1.70.

Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $0.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.03. The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $113.30 million. Natus Medical had a negative net margin of 8.62% and a positive return on equity of 10.75%. Natus Medical’s revenue for the quarter was down 10.7% on a year-over-year basis. During the same quarter last year, the business earned $0.24 EPS. On average, equities research analysts expect that Natus Medical will post 1.27 EPS for the current fiscal year.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Read More: Trading Options- What is a Strangle?

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.